Immune reconstitution inflammatory syndrome from Penicillium marneffei in an HIV-infected child: a case report and review of literature
© Sudjaritruk et al; licensee BioMed Central Ltd. 2012
Received: 10 May 2011
Accepted: 31 January 2012
Published: 31 January 2012
Disseminated Penicillium marneffei infection is one of the most common HIV-related opportunistic infections in Southeast Asia. Immune reconstitution inflammatory syndrome (IRIS) is a complication related to antiretroviral therapy (ART)-induced immune restoration. The aim of this report is to present a case of HIV-infected child who developed an unmasking type of IRIS caused by disseminated P. marneffei infection after ART initiation.
A 14-year-old Thai HIV-infected girl presented with high-grade fever, multiple painful ulcerated oral lesions, generalized non-pruritic erythrematous skin papules and nodules with central umbilication, and multiple swollen, warm, and tender joints 8 weeks after ART initiation. At that time, her CD4+ cell count was 7.2% or 39 cells/mm3. On admission, her repeated CD4+ cell count was 11% or 51 cells/mm3 and her plasma HIV-RNA level was < 50 copies/mL. Her skin biopsy showed necrotizing histiocytic granuloma formation with neutrophilic infiltration in the upper and reticular dermis. Tissue sections stained with hematoxylin and eosin (H&E), periodic acid-Schiff (PAS), and Grocott methenamine silver (GMS) stain revealed numerous intracellular and extracellular, round to oval, elongated, thin-walled yeast cells with central septation. The hemoculture, bone marrow culture, and skin culture revealed no growth of fungus or bacteria. Our patient responded well to intravenous amphotericin B followed by oral itraconazole. She fully recovered after 4-month antifungal treatment without evidence of recurrence of disease.
IRIS from P. marneffei in HIV-infected people is rare. Appropriate recognition and properly treatment is important for a good prognosis.
Penicillium marneffei is a dimorphic fungus which can cause a fatal systemic mycosis in human immunodeficiency virus (HIV)-infected patients. This organism is endemic in tropical Asia, especially Thailand, northeastern India, China, Hong Kong, Vietnam, and Taiwan [1–6]. Disseminated P. marneffei infection is one of the most common HIV-related opportunistic infections in northern Thailand . The typical manifestations of P. marneffei infection in HIV-infected individuals include fever, anemia, weight loss, skin lesions, generalized lymphadenopathy, and hepatomegaly [5, 7]. The primary treatment with amphotericin B and itraconazole and secondary prophylaxis with itraconazole are very effective regimens . Patients who do not receive timely and appropriate antifungal treatment have poor outcomes . Immune reconstitution inflammatory syndrome (IRIS) is a complication related to antiretroviral therapy (ART)-induced immune restoration. IRIS manifests as a paradoxical exacerbation of previously treated opportunistic infections (paradoxical or worsening IRIS) or as an unmasking of subclinical, untreated infections (unmasking IRIS) [9–12]. It is a consequence of exaggerated activation of the immune response against infectious organisms [13, 14]. In this report, we present a case of HIV-infected child with IRIS from disseminated P. marneffei infection.
A 14-year-old Thai girl presented at a provincial hospital with fever, oral ulcers, disseminated papular lesions and multiple joint pain for 4 weeks. Twelve weeks before this admission, she was diagnosed as a case of perinatal HIV infection after presenting with disseminated herpes zoster infection and Pneumocystis jirovecii pneumonia (PJP). At that time, her CD4+ cell count was 7.2% or 39 cells/mm3. Plasma HIV-RNA level was not obtained. She was started on GPOvirS30® (a fixed drug combination of stavudine 30 mg, lamivudine 150 mg and nevirapine 200 mg) 1 tablet twice daily and PJP prophylaxis with trimethoprim-sulfamethoxazole. Eight weeks after starting ART she developed fever, multiple oral ulcers, disseminated papular lesions over the face, body, and extremities, and severe pain in many joints. The symptoms did not respond to many kinds of oral antibiotics and she was referred to Chiang Mai University (CMU) Hospital.
Laboratory results on the day of admission
White blood count (×109/L)
Absolute neutrophil count
Absolute lymphocyte count
The patient was treated with intravenous amphotericin B at a dosage of 0.7 mg/kg for 2 weeks along with paracetamol and ibuprofen, followed by oral itraconazole at a dosage of 5 mg/kg twice daily orally. She responded well to treatment. Her fever, skin lesions, and joints pain gradually resolved. She was discharged with a plan to complete a 10-week course of oral itraconazole therapy followed by the maintenance therapy with oral itraconazole at a reduced dosage of 5 mg/kg daily. Her skin lesions and joints pain resolved after 4 weeks of antifungal treatment, and itraconazole was discontinued after 4 months of maintenance treatment. After 1 year of therapy, she had gained 4 kg weight without recurrence of P. marneffei infection. Her repeated CD4+ cell count had risen to 21.1% or 269 cells/mm3. Her plasma HIV RNA level was undetectable (< 50 copies/mL).
We reported a case of HIV-infected child who developed an unmasking IRIS caused by disseminated P. marneffei infection 8 weeks after ART initiation. After treatment with antifungal therapy, amphotericin B followed by itraconazole, she had fully recovery without evidence of recurrence.
IRIS is a manifestation of vigorous immune recovery which usually occurs within a few weeks to months after potent ART initiation in advanced stage HIV-infected patients. This inflammatory reaction is directed against pathogens causing latent or subclinical infection. The majority of patients present with unusual manifestations of opportunistic infections, most often while the number of CD4+ cell count is increasing and/or the plasma HIV RNA level is decreasing [11, 12, 15, 16]. This syndrome can be severe, and results in significant morbidity and occasional mortality. The information about incidence and spectrum of IRIS in HIV-infected children was limited. Puthanakit et al. reported an incidence of 19% of IRIS in advanced stage Thai HIV-infected children with the median onset of 4 weeks (range, 2-31) after ART commencement. The three major causative pathogens were mycobacterial spp. (43.8%), both Mycobacterium tuberculosis (TB) and non-tuberculous mycobacterium, varicella zoster virus (VZV) (21.9%), and herpes simplex virus (HSV) (21.9%) . Recently, Smith et al. reported an incidence of 21% of IRIS in South African HIV-infected children at a median of 16 days (range, 7-115 days) post-ART initiation. Bacillus Calmette-Guérin reaction (71%) and TB (35.3%) were the most common conditions in their children . Similarly, Wang et al. reported an incidence of 20% of IRIS (19.8 events per 100 person years) in HIV-infected children in Peru with 6.6 weeks (range, 2-32) median time to IRIS. The most common IRIS events were VZV infection (33.3%), HSV labialis (33.3%), and TB infection (22.2%) .
Our patient developed symptoms 8 weeks after the initiation of ART, which is a common period for IRIS development. They included fever, multiple painful oral ulcers, disseminated umbilicated papular skin lesions over the face, body and extremities, and multiple swollen, warm, and tender joints which are typical clinical presentations of disseminated P. marneffei infection. Tissue sections of the skin biopsy stained with H&E, PAS, and GMS revealed numerous yeast cells of P. marneffei, but culture did not yield the organism These signs and symptoms, especially prominent inflammatory articular manifestations, and an excessive inflammation reaction in histopathology of the skin biopsyspecimen demonstrated vigorous immune recovery which acted on unviable P. marneffei antigens. Improvement of her immune response was also evidenced by her rising CD4+ cell count and undetectable plasma HIV RNA level. The improved immune response had unmasked a previously quiescent P. marneffei infection causing the patient's symptoms.
Immune reconstitution inflammatory syndrome with disseminated Penicillium marneffei infection in HIV-infected patients: Literature review
Country reported year
Status before ART commencement
Type of ART
Type of IRIS
Time to IRIS onse
Status during IRIS presentation
Method for diagnosis
CD4 cell count (cells/mm3)
Viral load (copies/mL)
CD4 cell count (cells/mm3)
Viral load (copies/mL)
fever, loss of weight and appetite, hepatosplenomegaly, herpes genitalis
d4T, 3TC, NVP
afebrile, pallor, mild icterus, cervical and axillary lymphadenopathy, hepatosplenomegaly
axillary LN biopsy-positive, LN culture-positive blood culture -positive,
AmphoB 0.6 MKD for 14 days, followed by itraconazole 400 mg/d for 10 wks, then MT with 200 mg/d
At 10 mo; 20 kg weight gain, decrease size of LN, liver, spleen, CD4 = 224 cells/mm3
fever, cough, weight loss, diarrhea, generalized papular umbilicated lesion, oral and esophageal candidiasis
d4T, 3TC, EFV
fever, severe arthritis, exacerbration of skin lesions, generalised lymphadenopathy
172 (wk 4)
fever, cough, loss of weight, diarrhea, oral candidiasis
d4T, 3TC, NVP
multiple erythrematous, scaly, papules and nodules with central necrosis on face extremities, scortum
160 (wk 2)
skin biopsy-positive, skin culture-positive, blood culture-negative
AmphoB 0.6 MKD only 1 dose, then itraconazole 400 mg/d for 2 mo, then MT with 200 mg/d
At 2 mo; 14 kg weight gain, skin lesions disappear
UK (traveled to Thailand)27, 2010
fever, loss of weight and appetite, PJP, molluscum contangiosum on face
TDF, FTC, EFV
multiple facial lesions, disseminated non-pruritic nodules, no hepatosplenomegaly
273 (wk 8)
3 log drop (wk 4)
AmphoB 0.6 MKD for 14 days, followed by itraconazole 600 mg/d for 10 wks, then MT with 200 mg/d
At 2 mo; skin lesions regress At 28 mo; CD4 = 375 cells/mm3, VL < 50 copies/mL
Thailand, 2011 (Ours)
fever, loss of weight and appetite, PJP, herpes zoster on trunk
d4T, 3TC, NVP
fever, severe osteoarthritis, disseminated non-pruritic papules and nodules with central necrosis, oral ulcer, no lymphadenopathy, no hepatosplenomegaly
51 (wk 14)
< 50 (wk 14)
skin biopsy-positive, skin culture-negative, blood culture-negative
AmphoB 0.7 MKD for 14 days then Itraconazole 5 MK twice daily for 10 weeks, then MT with 5 MKD for 4 months
At 12 mo; 4 kg weight gain, CD4 = 269 cells/mm3, VL < 50 copies/mL
Diagnosis of infection by P. marneffei is usually made by identifying the fungus in clinical specimens by microscopy and culture. In addition, P. marneffei can be seen in histopathological sections stained with H&E, GMS, or PAS stain, which typically appears as unicellular round to oval yeast cells with transverse septum in macrophage or histiocyte . This finding is unique to infection with P. marneffei. All 4 previously reported cases had evidences of the fungus in the clinical specimens, including blood, skin biopsies, and lymph node biopsies and culture [21–24]. However, in our reported case, we found the evidences of organism in histopathological sections with special stains but could not identify fungus by culture of the clinical specimens. This might be due to the fact that the organism was already killed by the immune system of the patient.
Treatment of disseminated P. marneffei infection is well described . Intravenous amphotericin B for 2 weeks followed by oral itraconazole for 10 weeks is recommended. Although itraconazole maintenance treatment was shown to prevent relapse of penicilliosis when the patients had CD4 cell count of 100 cells/μl or greater for at least 6 months after HAART , our patient who unintentionally discontinued maintenance treatment after 4-month therapy without knowing the CD4 cell count did not have relapse. Details of treatments and outcomes were available in 3 of 4 previously reported cases (Table 2). Two cases (case 1, 4) were treated with intravenous amphotericin B for 2 weeks, followed by oral itraconazole for 10 weeks. The other case (case 3) received single dose of intravenous amphotericin B because the patient refused to stay in the hospital. Therefore, he was treated by only itraconazole orally for 8 weeks. All 3 cases were continued on maintenance treatment with oral itraconazole along with the ART. Their symptoms improved markedly after 2-10 months of the therapy.
In summary, IRIS is not a rare condition, especially in the ART era. IRIS caused by P. marneffei infection will be increasingly recognized in the endemic area of the fungus. It requires appropriate recognition and proper treatment. The clinicians' awareness is crucial to ensure a good prognosis.
Written informed consent was obtained from the parents of the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
This study was approved by Ethics Committee of Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
The authors would like to thank Pannee Visrutaratna, Professor of Radiology, Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand for reviewing the radiological studies of this patient. The authors also thank Kornkanok Sukapan, Assistant Professor of Pathology, Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand for performing the organism identification. We wish to thank the National Research University Project (Chiang Mai University) under Thailand's Office of the Higher Education Commission for supporting the publication.
- Chiang CT, Leu HS, Wu TL, Chan HL: Penicillium marneffei fungemia in an AIDS patient: the first case report in Taiwan. Changgeng Yi Xue Za Zhi. 1998, 21: 206-210.PubMedGoogle Scholar
- Deng Z, Ribas JL, Gibson DW, Connor DH: Infections caused by Penicillium marneffei in China and Southeast Asia: review of eighteen published cases and report of four more Chinese cases. Rev Infect Dis. 1988, 10: 640-652. 10.1093/clinids/10.3.640.View ArticlePubMedGoogle Scholar
- Hien TV, Loc PP, Hoa NT, Duong NM, Quang VM, McNeil MM, et al: First cases of disseminated Penicilliosis marneffei infection among patients with acquired immunodeficiency syndrome in Vietnam. Clin Infect Dis. 2001, 32: e78-80. 10.1086/318703.View ArticlePubMedGoogle Scholar
- Ranjana KH, Priyokumar K, Singh TJ, Gupta ChC, Sharmila L, Singh PN, et al: Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India. J Infect. 2002, 45: 268-271. 10.1053/jinf.2002.1062.View ArticlePubMedGoogle Scholar
- Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T: Disseminated Penicillium marneffei infection in Southeast Asia. Lancet. 1994, 344: 110-113. 10.1016/S0140-6736(94)91287-4.View ArticlePubMedGoogle Scholar
- Wong KH, Lee SS, Chan KC, Choi T: Redefining AIDS: case exemplified by Penicillium marneffei infection in HIV-infected people in Hong Kong. Int J STD AIDS. 1998, 9: 555-556.View ArticlePubMedGoogle Scholar
- Vanittanakom N, Sirisanthana T: Penicillium marneffei infection in patients infected with human immunodeficiency virus. Curr Top Med Mycol. 1997, 8: 35-42.PubMedGoogle Scholar
- Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T: A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med. 1998, 339: 1739-1743. 10.1056/NEJM199812103392403.View ArticlePubMedGoogle Scholar
- Singh N: Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis. 2007, 7: 395-401. 10.1016/S1473-3099(07)70085-3.View ArticlePubMedGoogle Scholar
- Lawn SD, Bekker LG, Miller RF: Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis. 2005, 5: 361-373. 10.1016/S1473-3099(05)70140-7.View ArticlePubMedGoogle Scholar
- Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, et al: Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine. 2002, 81: 213-227. 10.1097/00005792-200205000-00005.View ArticlePubMedGoogle Scholar
- French MA, Price P, Stone SF: Immune restoration disease after antiretroviral therapy. AIDS. 2004, 18: 1615-1627. 10.1097/01.aids.0000131375.21070.06.View ArticlePubMedGoogle Scholar
- French MA: HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis. 2009, 48: 101-107. 10.1086/595006.View ArticlePubMedGoogle Scholar
- Boulware DR, Callens S, Pahwa S: Pediatric HIV immune reconstitution inflammatory syndrome. Curr Opin HIV AIDS. 2008, 3: 461-467. 10.1097/COH.0b013e3282fe9693.View ArticlePubMedPubMed CentralGoogle Scholar
- Murdoch DM, Venter WD, Van RA, Feldman C: Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther. 2007, 4: 9-10.1186/1742-6405-4-9.View ArticlePubMedPubMed CentralGoogle Scholar
- Hirsch HH, Kaufmann G, Sendi P, Battegay M: Immune reconstitution in HIV-infected patients. Clin Infect Dis. 2004, 38: 1159-1166. 10.1086/383034.View ArticlePubMedGoogle Scholar
- Puthanakit T, Oberdorfer P, Akarathum N, Wannarit P, Sirisanthana T, Sirisanthana V: Immune reconstitution syndrome after highly active antiretroviral therapy in HIV-infected Thai children. Pediatr Infect Dis J. 2006, 25: 53-58. 10.1097/01.inf.0000195618.55453.9a.View ArticlePubMedPubMed CentralGoogle Scholar
- Smith K, Kuhn L, Coovadia A, Meyers T, Hu CC, Reitz C, et al: Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS. 2009, 23: 1097-1107. 10.1097/QAD.0b013e32832afefc.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang ME, Castillo ME, Montano SM, Zunt JR: Immune reconstitution inflammatory syndrome in human immunodeficiency virus-infected children in Peru. Pediatr Infect Dis J. 2009, 28: 900-903. 10.1097/INF.0b013e3181a4b7fa.View ArticlePubMedPubMed CentralGoogle Scholar
- Sirisanthana V, Sirisanthana T: Disseminated Penicillium marneffei infection in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1995, 14: 935-940. 10.1097/00006454-199511000-00003.View ArticlePubMedGoogle Scholar
- Gupta S, Mathur P, Maskey D, Wig N, Singh S: Immune restoration syndrome with disseminated Penicillium marneffei and cytomegalovirus co-infections in an AIDS patient. AIDS Res Ther. 2007, 4: 21-10.1186/1742-6405-4-21.View ArticlePubMedPubMed CentralGoogle Scholar
- Saikia L, Nath R, Biswanath P, Hazarika D, Mahanta J: Penicillium marneffei infection in HIV infected patients in Nagaland & immune reconstitution after treatment. Indian J Med Res. 2009, 129: 333-334.PubMedGoogle Scholar
- Saikia L, Nath R, Hazarika D, Mahanta J: Atypical cutaneous lesions of Penicillium marneffei infection as a manifestation of the immune reconstitution inflammatory syndrome after highly active antiretroviral therapy. Indian J Dermatol Venereol Leprol. 2010, 76: 45-48. 10.4103/0378-6323.58678.View ArticlePubMedGoogle Scholar
- Ho A, Shankland GS, Seaton RA: Penicillium marneffei infection presenting as an immune reconstitution inflammatory syndrome in an HIV patient. Int J STD AIDS. 2010, 21: 780-782. 10.1258/ijsa.2010.010164.View ArticlePubMedGoogle Scholar
- Jayanetra P, Nitiyanant P, Ajello L, Padhye AA, Lolekha S, Atichartakarn V, et al: Penicilliosis marneffei in Thailand: report of five human cases. AmJTrop Med Hyg. 1984, 33: 637-644.Google Scholar
- Louthrenoo W, Thamprasert K, Sirisanthana T: Osteoarticular penicilliosis marneffei. A report of eight cases and review of the literature. Br J Rheumatol. 1994, 33: 1145-1150. 10.1093/rheumatology/33.12.1145.View ArticlePubMedGoogle Scholar
- Chan YF, Woo KC: Penicillium marneffei osteomyelitis. J Bone Joint Surg Br. 1990, 72: 500-503.PubMedGoogle Scholar
- Drouhet E: Penicilliosis due to Penicillium marneffei: a new emerging systemic mycosis in AIDS patients travelling or living in Southeast Asia. Review 44 cases reported in HIV infected patients during the last 5 years compared to 44 cases of non AIDS patients reported over 20 years. J Mycol Med. 1993, 4: 195-224.Google Scholar
- Vanittanakom N, Cooper CR, Fisher MC, Sirisanthana T: Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev. 2006, 19: 95-110. 10.1128/CMR.19.1.95-110.2006.View ArticlePubMedPubMed CentralGoogle Scholar
- Sirisanthana T, Supparatpinyo K, Perriens J, Nelson KE: Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis. 1998, 26: 1107-1110. 10.1086/520280.View ArticlePubMedGoogle Scholar
- Chaiwarith R, Charoenyos N, Sirisanthana T, Supparatpinyo K: Discontinuation of secondary prophylaxis against penicilliosis marneffei in AIDS patients after HAART. AIDS. 2007, 21: 365-367. 10.1097/01.aids.0000253374.19966.f9.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/12/28/prepub